Nico Ghilardi

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9548629/nico-ghilardi-publications-by-year.pdf
Version: 2024-04-28

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67 papers	11,066 citations	46 h-index	67 g-index
67 ext. papers	12,143 ext. citations	11.9 avg, IF	5.64 L-index

#	Paper	IF	Citations
67	The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. *PLoS ONE*, **2021**, 16, e0244439	3.7	3
66	TGF□ and TGF□ isoforms drive fibrotic disease pathogenesis. *Science Translational Medicine*, **2021** , 13,	17.5	10
65	The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. *Science Signaling*, **2020**, 13,	8.8	11
64	30 Years of Biotherapeutics Development-What Have We Learned?. *Annual Review of Immunology*, **2020**, 38, 249-287	34.7	6
63	The role of IL-22 in intestinal health and disease. *Journal of Experimental Medicine*, **2020**, 217, e20192195	16.6	65
62	Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1522-1531	2.9	15
61	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton□s Tyrosine Kinase Inhibitor in Early Clinical Development. *Journal of Medicinal Chemistry*, **2018**, 61, 2227-2245	8.3	119
60	NF-□B inducing kinase is a therapeutic target for systemic lupus erythematosus. *Nature Communications*, **2018**, 9, 179	17.4	58
59	Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma. *Science Translational Medicine*, **2018**, 10,	17.5	16
58	Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-□B Inducing Kinase. *Journal of Medicinal Chemistry*, **2018**, 61, 6801-6813	8.3	25
57	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4370-4376	2.9	10
56	T Cell-Derived IL-10 Impairs Host Resistance to Infection. *Journal of Immunology*, **2017**, 199, 613-623	5.3	62
55	IL-27 Directly Enhances Germinal Center B Cell Activity and Potentiates Lupus in Sanroque Mice. *Journal of Immunology*, **2016**, 197, 3008-3017	5.3	17
54	Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression. *Blood*, **2016**, 128, 2068-2082	2.2	31
53	Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice. *Toxicology and Applied Pharmacology*, **2016**, 300, 47-54	4.6	24
52	Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection. *Journal of Experimental Medicine*, **2015**, 212, 1449-63	16.6	52
51	Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response. *Science Signaling*, **2015**, 8, ra122	8.8	24

50	Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 13942-7	11.5	65
49	Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. *Journal of Immunology*, **2014**, 193, 3600-12	5.3	130
48	Oral-resident natural Th17 cells and γδT cells control opportunistic Candida albicans infections. *Journal of Experimental Medicine*, **2014**, 211, 2075-84	16.6	173
47	The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal Candida albicans infections. *Infection and Immunity*, **2014**, 82, 1173-80	3.7	49
46	Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3592-8	2.9	17
45	Lead identification of novel and selective TYK2 inhibitors. *European Journal of Medicinal Chemistry*, **2013**, 67, 175-87	6.8	61
44	2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5014-21	2.9	30
43	Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 4521-36	8.3	56
42	Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. *Journal of Medicinal Chemistry*, **2013**, 56, 4764-85	8.3	48
41	Intestinal lamina propria dendritic cells maintain T cell homeostasis but do not affect commensalism. *Journal of Experimental Medicine*, **2013**, 210, 2011-24	16.6	121
40	A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. *Journal of Immunology*, **2013**, 191, 2205-16	5.3	69
39	Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7627-33	2.9	18
38	Bystanders not so innocent after all. *Immunity*, **2012**, 36, 901-3	32.3	
37	Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. *Journal of Medicinal Chemistry*, **2012**, 55, 6176-93	8.3	43
36	Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 5901-21	8.3	77
35	Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. *Mucosal Immunology*, **2012**, 5, 99-109	9.2	78
34	Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. *PLoS ONE*, **2011**, 6, e25038	3.7	81
33	IL-27 promotes T cell-dependent colitis through multiple mechanisms. *Journal of Experimental Medicine*, **2011**, 208, 115-23	16.6	103

32	A mouse knockout library for secreted and transmembrane proteins. *Nature Biotechnology*, **2010**, 28, 749-55	44.5	258
31	IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. *Journal of Experimental Medicine*, **2010**, 207, 2895-906	16.6	160
30	Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. *Journal of Experimental Medicine*, **2010**, 207, 7-16	16.6	44
29	IL-23 is required for protection against systemic infection with Listeria monocytogenes. *Journal of Immunology*, **2009**, 183, 8026-34	5.3	87
28	Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. *Journal of Experimental Medicine*, **2009**, 206, 3047-59	16.6	220
27	Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. *Cell Stem Cell*, **2009**, 4, 559-67	18	136
26	Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nature Medicine*, **2008**, 14, 282-9	50.5	1429
25	Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. *Journal of Immunology*, **2008**, 180, 2752-6	5.3	172
24	Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. *Experimental Hematology*, **2007**, 35, 78-86	3.1	23
23	The biology and therapeutic potential of interleukin 27. *Journal of Molecular Medicine*, **2007**, 85, 661-72	5.5	105
22	IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. *Journal of Experimental Medicine*, **2007**, 204, 481-7	16.6	65
21	Targeting the development and effector functions of TH17 cells. *Seminars in Immunology*, **2007**, 19, 383-93	10.7	64
20	Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. *Journal of Experimental Medicine*, **2006**, 203, 1805-15	16.6	243
19	CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. *Cell*, **2006**, 124, 915-27	56.2	405
18	Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. *Nature Immunology*, **2006**, 7, 929-36	19.1	681
17	IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. *Journal of Immunology*, **2005**, 175, 788-95	5.3	388
16	Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. *Journal of Experimental Medicine*, **2005**, 202, 761-9	16.6	487
15	Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. *Journal of Immunology*, **2004**, 172, 2827-33	5.3	167

14	IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. *Journal of Immunology*, **2004**, 173, 7490-6	5.3	114
13	Hereditary Thrombocythemia **2004**, 99-105		
12	IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 15047-52	11.5	367
11	Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *Journal of Biological Chemistry*, **2003**, 278, 1910-4	5.4	1382
10	A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. *Journal of Biological Chemistry*, **2002**, 277, 16831-6	5.4	60
9	Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. *British Journal of Haematology*, **2000**, 110, 104-9	4.5	38
8	Development of Th1-type immune responses requires the type I cytokine receptor TCCR. *Nature*, **2000**, 407, 916-20	50.4	321
7	A Single-Base Deletion in the Thrombopoietin (TPO) Gene Causes Familial Essential Thrombocythemia Through a Mechanism of More Efficient Translation of TPO mRNA. *Blood*, **1999**, 94, 1480-1482	2.2	72
6	Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 698-702	11.5	59
5	Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. *British Journal of Haematology*, **1999**, 107, 310-6	4.5	114
4	Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. *Journal of Neuroscience*, **1998**, 18, 559-72	6.6	648
3	Thrombopoietin Production Is Inhibited by a Translational Mechanism. *Blood*, **1998**, 92, 4023-4030	2.2	61
2	The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. *Molecular Endocrinology*, **1997**, 11, 393-9		269
1	Defective STAT signaling by the leptin receptor in diabetic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 6231-5	11.5	660